Sponge is now "leading brand in the vaginal contraceptive category in both dollars and units sold to drugstores," VLI said in May 11 first quarter report to shareholders. Nearly 13 mil. sponges have been sold to about 500,000 users. For quarter ended March 31 VLI volume increased about 45% to $3.4 mil.; the firm showed net earnings of $305,027 v. a $32,817 loss in same quarter last year.
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.